Transcatheter Versus Surgical Aortic Valve Replacement in Hypertrophic Cardiomyopathy Patients with Aortic Stenosis

Mohammed Mhanna1, Abdul Mannan Khan Minhas2, Robert W Ariss3

  • 1Department of Internal Medicine, The University of Toledo, Toledo, OH.

Insights

Transcatheter aortic valve replacement (TAVR) shows lower in-hospital mortality and fewer complications than surgical aortic valve replacement (SAVR) in hypertrophic cardiomyopathy patients with severe aortic stenosis. Further research on long-term outcomes is needed.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Interventional Cardiology

Background:

  • Severe aortic stenosis (AS) is treated with surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR).
  • Patients with hypertrophic cardiomyopathy (HCM) were excluded from key TAVR trials, limiting comparative data.
  • Understanding TAVR vs. SAVR outcomes in HCM patients with AS is crucial.

Purpose of the Study:

  • To compare in-hospital outcomes and resource utilization between TAVR and SAVR in adult patients with HCM and severe AS.
  • To evaluate the safety and efficacy of TAVR versus SAVR in this specific patient population.

Main Methods:

  • Analysis of the 2016-2019 National Inpatient Sample database.
  • Identification of adult hospitalizations with HCM undergoing SAVR or TAVR for severe AS.
  • Comparison of primary (in-hospital mortality) and secondary outcomes, including complications and resource utilization.

Main Results:

  • TAVR was associated with lower in-hospital mortality compared to SAVR in HCM patients with AS.
  • TAVR demonstrated reduced rates of bleeding requiring transfusion, acute kidney injury, and shorter hospital stays.
  • No significant differences were observed in cardiac arrest, new permanent pacemaker, or cardiac tamponade rates between TAVR and SAVR.

Conclusions:

  • Transcatheter aortic valve replacement (TAVR) offers a lower-risk alternative to surgical aortic valve replacement (SAVR) for hypertrophic cardiomyopathy patients with isolated severe aortic stenosis.
  • TAVR is linked to decreased in-hospital mortality, fewer peri-procedural complications, and improved resource utilization.
  • Further investigation into the long-term efficacy and safety of TAVR versus SAVR in this cohort is warranted.

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
32
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
76
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
45
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
57
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
52